Investing in the cannabis market in 2019 could be one of the smartest financial decisions you can make. With MedMen stock on investors’ lips, is it worth considering MedMen Enterprises (CSE:MMEN) (OTCQB:MMNFF) for your portfolio this year?

MedMen Stock

Before we get into the nitty-gritty, it’s worth noting that 2019 is considered a transitionary year for cannabis. As such, it is an opportunistic time for investors if they choose the right stocks.

It’s transitionary for two reasons:

1. The hype that preceded cannabis legalization in Canada is just over. No year was more hype-tastic for cannabis stocks than 2018 when investors threw money at the sector predominantly on hear-say and ‘could be’s’ and not on actual metrics. (For the most part anyway).
2. With the market in full swing, we now have actual metrics. Numbers count for a lot when you are a company seeking out a position in a crowded, competitive space. Companies that are making the right strategic moves and are showing good bottom lines will most likely be the same ones that return a legitimate profit to investors.

And on this point, enter MedMen Enterprises.

Strategy and Numbers

MedMen stock looks set to skyrocket in 2019, and this is off the back of very healthy revenue. MedMen Enterprises reported amazing Q4 2018 results, which set it apart from competitors.

Highlights include:

• Systemwide revenue reached $20.6 million, up 1,317% from $1.5 million in Q4 2017 and 44% from $14.3 million in Q3 2018.
• The fiscal year 2018 showed systemwide revenue of $39.8 million, up 1,390% from $2.7 million in the fiscal year 2017.

Operations

MedMen operates a whopping 69 licensed dispensaries and 17 cultivation and production facilities across 12 states. This puts it an ideal position to cater to a growing and lucrative marijuana demand across America’s expanding cannabis industry.

And as time ticks along, the normalization of marijuana laws represent an unstoppable trend. More and more US states are legalizing cannabis—if not due to public demand, then for the massive tax revenue the industry generates.

Based on those numbers and those facts, MedMen stock is set to soar. The company did lose money early in 2018. This was predominantly due to temporary investments in future growth that were a market necessity for most cannabis companies. As said, this is a transitionary year for cannabis, we can see the true winners in this market begin to shine, and many stocks are still at attractive prices.